CEO Roger Susi enters new 10b5-1 plan to sell shares over 12 months

IRADIMED CORP

Plan replaces prior June 2021 plan; allows daily sales from Nov 22, 2021 to Nov 21, 2022.
Sales subject to minimum market price threshold; executed shares disclosed via Form 4 filings.
Purpose: increase public float in a non-dilutive manner.
Plan terminates on earlier of Nov 21, 2022, full execution, or termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.